Actuarial long-term disease-free survival (DFS) for adults with acute lymphoblastic leukemia (ALL) less than 60 years of age is 29-39% in large multicentre studies. [1] [2] [3] [4] We have previously reported favorable outcome for patients less than 60 years of age treated according to our institutional protocol: actuarial 8-year overall survival (OS) 47% and DFS 44%. 5 Actual survival, however, is rarely reported in the medical literature. The purpose of this report is to present the actual 8-year survival for adults with ALL treated in our hospital.
Induction therapy included prednisone, vincristine, L-asparaginase, doxorubicin and cyclophosphamide. Consolidation was daunorubicin, cytarabine and 6-thioguanine, followed by two courses of high-dose methotrexate and 6-mercaptopurine orally for 7 weeks. Maintenance was prednisone, vincristine, doxorubicin and cyclophosphamide followed by methotrexate alternating with 6-mercaptopurine orally as part of 12-week re-induction cycles for 3 years. Central nervous system prophylaxis consisted of 10 intrathecal injections of methotrexate. The protocol has been described in detail elsewhere. 5 Highdose methotrexate was increased from 500 to 1500 mg/m 2 through 1000 mg/m 2 following our previous report, but apart from this dose escalation the protocol has been unchanged during the study period. Patients in 2.complete remission (2.CR) with a suitable donor were allografted as part of salvage therapy. From the early 1990s, patients with high-risk ALL (t(9;22), 11q23 abnormalities, complex karyotype, pro-B or pro-T immunophenotype) were allografted in 1.complete remission (1.CR), if a suitable donor was available.
Between October 1982 and December 1998, 105 patients, aged 15-59 years, received treatment for ALL with a curative intention in our hospital (Table 1) . Patients were followed to death or for a minimum of 96 months. Eight patients died during induction therapy, leaving behind 97 patients eligible for response evaluation. CR was accomplished in 94 patients (94/105 patients; 90%). Three patients had therapy-refractory leukemia and died from progressive disease. Five patients with high-risk ALL were allografted in 1.CR, and 89 patients were offered chemotherapy alone as their first-line therapy. Actual 8-year OS and DFS were 50% (53/105 patients) and 50% (52/ 105 patients), respectively. Following chemotherapy alone, 49 patients (47% of the total cohort and 51% of those achieving remission) were alive in remission at 8 years. However, very late relapses do occur. One patient relapsed at 135 months, and died during allografting in 2.CR. Of 94 patients 37, (39%) have relapsed following first-line therapy; 35 of 89 patients relapsed following chemotherapy and 2 of 5 patients following an allograft in 1.CR. After achieving 1.CR, 41 patients have died: 35 due to relapse and 6 in remission (3 during maintenance chemotherapy, 1 from a second malignancy and 2 within the first months of an allograft). Allografting in 2.CR was performed in 12 patients. Two patients enjoy a sustained remission, six have died from relapse, three died from transplant-related mortality and one is alive with relapse 8 years after allografting. Abbreviations: ALL, acute lymphoblastic leukemia; F, female; M, male.
Letters to the Editor
Our results are superior to results reported from large multicentre trials (DFS 29-39%). Our study is a relatively large, single-center study involving patients with a low median age at diagnosis. Outcome is often superior in single-center studies compared to multicenter studies, and age is a well-recognized prognostic factor. However, these factors cannot fully account for our favorable results. Our treatment protocol is rather intensive and contains more glucocorticoids, vincristine, L-asparaginase, methotrexate and 6-mercaptopurine than most adult protocols. In this respect, our protocol is in line with pediatric protocols. Favorable outcome for adolescents treated according to pediatric protocols (DFS 64-67%) compared to adult protocols (34-41%) has recently been reported, and the results have been attributed to treatment intensity with particular reference to the drugs specified above. [6] [7] [8] In patients less than 25 years of age, 8-year DFS is 67% in our study. This fits very well with the results reported in studies in which adolescents have been treated according to pediatric protocols. The Abl tyrosine kinase inhibitor imatinib mesylate (IM) now represents the new standard treatment of chronic myeloid leukemia (CML). 1 However, a growing number of CML patients develop imatinib resistance and several mechanisms of resistance have been described, including BCR-ABL mutations. While most mutant forms are sensitive to new secondgeneration tyrosine kinase inhibitors (TKIs) (dasatinib and nilotinib), the T315I mutation remains completely refractory to imatinib, as well as to these new agents. We report here a CML patient harboring a T315I BCR-ABL mutation while on IM treatment, which completely disappeared when he was treated with HHT.
GE
A 63-year-old man was referred for a chronic-phase Philadelphia-positive (Ph þ ) CML in August 2003. Sokal and Hasford scores led to a high-risk classification. Bone marrow conventional cytogenetic analysis demonstrated a t(9;22) (q34;q11) in 25/25 metaphases analyzed, with no additional chromosomal abnormality. He had no sibling histocompatible donor. The patient was enrolled in the CML French Group phase III prospective trial (SPIRIT) and was randomized to the IM 400 mg þ cytarabine (Ara-C) treatment arm. A complete hematological response (CHR) was achieved within 1 month, while only a minor cytogenetic response was obtained after 1 year of treatment. Despite IM dose escalation to 600 mg daily, the percentage of Ph þ metaphases increased from 53 to 73% after 3 months. The patient was then enrolled in AFR10, a phase I/II prospective study combining IM 600 mg/ day with PegIFN-2a 90 mg subcutaneously weekly. According to the protocol, the patient was serially assessed every 3 months for BCR-ABL mutation detection. After 9 months of the AFR10 treatment, a T315I mutation was detected. IM was immediately discontinued, and PegIFN was continued until obtaining the authorization for compassionate use of HHT. One month after imatinib discontinuation, the patient received three courses of subcutaneous HHT given at 2.5 mg/m 2 /day for 11, 9 and 5 days, respectively. The HHT dose was reduced because of grade 3-4 hematologic toxicity (neutro-
